Thermo Fisher will buy The Binding Site
- Thermo Fisher said it agreed to acquire U.K.-based diagnostics firm The Binding Site Group for 2.25 billion pounds ($2.6 billion).
- Binding Site makes two blood tests for multiple myeloma called Freelite and Hevylite.
- The deal will add to Thermo Fisher’s specialty diagnostics portfolio, CEO Marc Casper said in a statement on Monday.
The Binding Site’s Freelite blood test measures serum-free light chains, a protein produced by immune cells. These types of tests are the standard of care for diagnosing multiple myeloma. Its Hevylite test is used to monitor multiple myeloma patients.
For more details go to Medtechdive site.